Brooks Laboratories — 360° view

Brooks Laboratories, a company in the Pharmaceuticals industry, reported revenue of ₹19 crore and net profit of ₹70 crore for the September 2026 quarter.

Brooks Laboratories (NSE: BROOKS) closed at ₹67.20 on 20 Nov 2026. Its market capitalisation is ₹198 crore and it trades at 68.5 times earnings.

Share price
₹67.20 (20 Nov 2026)
Market cap
₹198 Cr (20 Nov 2026)
P/E
68.50 (20 Nov 2026)
Revenue
₹19 Cr (September 2026 quarter)
Net profit
₹70 Cr (September 2026 quarter)
ROCE
5.04% (FY26)
ROE
4.68% (FY26)
Book value
₹65.3 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹75.60 / ₹52.97 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: BROOKS

Incorporated in 2002, Brooks Laboratories Ltd is a pharmaceutical company working on contract basis catering to the critical care segment

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.